Related Experiment Video
Updated: Jan 2, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus
Pierre Gantner1,2, Mojgan Hessamfar3, Mohamed Faouzi Souala4
1Laboratory of Molecular Virology, Hôpitaux Universitaires de Strasbourg, Rennes, France.
Abstract:
We evaluated an elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis.
Clinical Trials Registration:
NCT02998320.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Subviral Agents
Retroviruses
Pharmacokinetics: Drug–Food and Drug–Viral Interactions

